Cizotinib is inhibitor of which receptor -
Ans. is 'a' i.e., Tyrosine kinase Crizotinib* It is a small molecule multitargeted tyrosine kinase receptor inhibitor targeting ALK, MET, ROS1 kinases.* By inhibiting ALK tyrosine kinase activity, crizotinib inhibits cell proliferation, induces G1 - S phase cell cycle arrest and apoptosis.* It is approved for the first line in management of metastatic non-small cell lung cancer with an ALK mutation.* The most common adverse effects associated with crizotinib are vision disorder, diarrhea and edema.* It is also associated with QT prolongation and bradycardia* Tumors invariably acquire resistance after one year of treatment. Mechanism of resistance include mutations in ATP binding pocket of the tyrosine kinase domain of ALK.
Tyrosine kinase
VEGF receptor
TNF alpha receptor
PDGF receptor
Immunomodulator